TL;DR
This paper presents an updated consensus from Chinese experts on using a combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic targeted drugs (AATDs) to treat advanced hepatocellular carcinoma (HCC). The goal is to "convert" unresectable tumors into resectable ones, enabling curative surgery and improving long-term survival for patients with this challenging disease.
What Problem Does This Paper Address?
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is often diagnosed at advanced stages when effective treatment options are limited, leading to poor prognoses. While traditional treatments like surgery or systemic therapies have limitations for advanced HCC, recent advancements in immunotherapy (ICIs) and targeted therapy (AATDs) have shown significant promise. This paper addresses the need for a standardized, expert-driven approach to integrating these novel therapies with surgical interventions, specifically focusing on "conversion therapy" – using these drugs to shrink tumors enough for surgical removal. The consensus aims to update previous guidelines and provide clear recommendations for clinical practice.
Methods
This document is not a research paper presenting novel experimental methods or datasets. Instead, it's an expert consensus statement. The "methods" involved:
- In-depth discussions: Leading domestic experts in hepatobiliary and pancreatic diseases, liver cancer, and surgery convened.
- Literature review: A comprehensive search of databases (PubMed, Web of Science, CNKI, Wanfang) and recent international conference abstracts was conducted.
- Evidence-based evaluation: Recommendations were graded using the Oxford Centre for Evidence-Based Medicine Grading system (levels 1-5) and categorized as Strong (A), Moderate (B), or Weak (C) recommendations.
- Consensus building: Opinions were discussed online, in writing, and through offline seminars, with final consensus achieved through voting (≥80% agreement).
- Registration: The consensus was registered on the International Practice Guideline Registration for Transparency (PREPARE) Platform.
Datasets
Not applicable. This is an expert consensus document, not a research study that collects or analyzes new data.
Key Insights and Ideas
- Conversion Therapy as a Bridge: The core idea is that ICIs + AATDs can act as a bridge, transforming unresectable tumors into surgically treatable ones, thereby offering a chance for a radical cure and improved long-term survival.
- ICI + AATD Synergy: The combination of ICIs and AATDs is highlighted as the preferred first-line treatment for advanced HCC, offering better outcomes than monotherapy and opening doors for conversion therapy.
- Sequential Surgery is Key: The ultimate goal of conversion therapy is to enable sequential curative surgery (hepatectomy or liver transplantation), which is crucial for achieving long-term survival benefits.
- Standardized Evaluation is Crucial: The consensus emphasizes the importance of standardized imaging (mRECIST) and tumor marker evaluations to assess treatment response and determine the optimal timing for surgery.
- Multidisciplinary Approach: Effective conversion therapy and subsequent management require a collaborative effort from a multidisciplinary team (MDT).
- Managing Adverse Events: While effective, ICIs and AATDs have associated adverse reactions that need careful monitoring and management, with specific guidelines provided.
Key Results
This consensus document doesn't present quantitative results in the traditional sense. Instead, it provides a set of recommendations and guidelines based on the synthesis of existing evidence and expert opinion. Key "results" include:
- Consensus on ICI + AATD: Strong recommendation (A) for using ICI + AATD regimens as the preferred approach for conversion therapy.
- Surgical Criteria: Detailed technical criteria for surgical resection after conversion therapy are outlined (e.g., Child-Pugh class A/B, adequate future liver remnant, ICG <20%).
- Evaluation Intervals: Recommendations for evaluating treatment response every three cycles (6-8 weeks) of conversion therapy, with flexibility for adjustment.
- Tumor Marker Significance: Acknowledgment of the role of AFP and PIVKA-II in predicting response, with significant decreases suggesting effectiveness.
- Pathological Evaluation: Emphasis on the importance of pathological examination of excised specimens for assessing treatment efficacy and guiding adjuvant therapy.
- Adverse Event Management: Principles for managing severe adverse reactions, including dose adjustment, discontinuation, and symptomatic treatment.
Limitations and Future Work
- Lack of Head-to-Head Trials: The authors acknowledge that high-level evidence from direct comparative randomized controlled trials for conversion therapy and sequential surgery is still lacking.
- Need for Further Validation: While promising, the long-term survival outcomes of some combined immuno-targeted therapy and local treatment strategies still require confirmation.
- Defining Optimal Timing: Determining the precise optimal timing for surgery after conversion therapy remains an area for further investigation.
- Standardization Challenges: Differences in patient characteristics, definitions of conversion success, and resectability criteria across studies present challenges for direct comparisons.
- Future Directions: The consensus implicitly points towards the need for more prospective studies, particularly randomized controlled trials, to further refine treatment strategies, optimize surgical timing, and validate the long-term benefits of this approach. The paper also highlights the ongoing development of adjuvant therapies and the importance of continued multidisciplinary collaboration.
Summary updated